Iambic Therapeutics (IAM) Joins The Nasdaq Composite, Is The Stock Already Pricey?

Iambic Therapeutics (IAM) was just added to the Nasdaq Composite Index after a busy October that included its US$150 million IPO and a US$184.6 million shelf registration. The recent Nasdaq Composite inclusion builds on a sharp positive swing in Iambic Therapeutics’ trading, with a 1-day share price return of 25.91% and a year-to-date share price return of 48.81%, signalling strong upward momentum in a short time frame. Capitalize on the momentum around Iambic Therapeutics by scanning a...